• Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

(970) 818-8343

info@cetya-therapeutics.com
Cetya Therapeutics Cetya Therapeutics
  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

News & Publications

News

Cetya Therapeutics announces advanced industries award

$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.

December 1, 2017Read More

Cetya Therapeutics announces STTR grant

$240,000 Grant will allow evaluation of Cetya’s HDAC inhibitors for treatment of sickle cell disease.

September 22, 2017Read More

Cetya Therapeutics announces seed round financing

$220,000 Round includes Canadian firm InSynchrony Ventures Inc Proceeds will advance oncology drug development. Fort…

May 8, 2017Read More

Publications

  1. Bowers, A.; West, N.; Taunton, J.; Schreiber, S. L.; Bradner, J. E.; and R. M. Williams, Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor. J Am Chem Soc. 2008, 130, 11219–22. >>
  2. Guerra-Bubb, J. M.; Bowers, A.; Smith, W. B.; Paranal, R.; Estiu, G.; Wiest, O.; Bradner, J. E.; and R. M. Williams, Synthesis and HDAC Inhibitory Activity of Isosteric Thiazoline-Oxazole Largazole Analogs. Bioorg. Med. Chem. Lett. 2013, 23, 6025–8. >>
  3. Bowers, A. A.; West, N.; Newkirk, T. L.; Troutman-youngman, A. E.; Schreiber, S. L.; Wiest, O.; Bradner, J. E.; and R. M. Williams, Synthesis and HDAC Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold. Org Lett. 2009, 11, 1301–1304. >>
  4. Bowers, A. A.; Greshock, T. J.; West, N.; Estiu, G.; Stuart, L.; Wiest, O.; Williams, R. M.; and J. E. Bradner, Synthesis and Conformation-Activity Relationships of the Peptide Isosteres of FK228 and Largazole. J Am Chem Soc. 2009, 131, 2900–2905. >>

HDACIs with best-in-class potency and isoform selective drug candidates

Learn More

Contact Us

We're currently offline. Send us an email and we'll get back to you, asap.

Send Message

Menu

  • Company
  • Leadership
  • Research & Development
    • Overview
    • Therapeutic Indications
  • Collaborations
  • News & Publications
  • Contact

Contact

  • (303) 895-8216
  • info@cetya-therapeutics.com

© 2018 · Cetya Therapeutics